DNA and Gene Cloning Services Market Growth Outlook and Strategic Analysis 2026 to 2035

InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2035"

DNA and Gene Cloning Services Market Size is valued at USD 3.68 Bn in 2025 and is predicted to reach USD 17.49 Bn by the year 2035 at a 17.0% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1357

The significant market companies are Bio-Techne, Curia, Eurofins, GenScript, MedGenome, Integrated DNA Technologies, Sino Biological, Syngene, Twist Bioscience, Thermo Fisher Scientific Inc., Charles River Laboratories, Eurofins Scientific, GenScript, Merck KGaA, Takara Bio Inc., Lonza, Sartorius AG, Creative Biogene, Cellecta, Inc., Synbio Technologies, TransGen Biotech Co., Ltd., Dobuss (Canvax), Azenta US, Inc., Macrogen, Inc., Codex DNA, Inc., Bio-Rad, and other key players.

Key Developments in the Market
• In Jan 2021, Codex DNA and Pfizer signed an early access collaboration and licencing agreement, which will allow Pfizer to use CodexDNA's novel enzymatic DNA synthesis technology in its research and development of mRNA-based vaccines and biotherapies. Codex DNA will be responsible for further developing the technology.
• In May 2020, GenScript just launched a GMP single-strand and double-strand DNA service to aid in the growth of gene and cell therapies. The announcement highlights GenScript's commitment to assisting entire non-viral cell therapy development through the IND-enabling and clinical stages.
• In Dec 2020, Thermo Fisher increased its plasmid DNA manufacturing clinical and commercial capabilities. Commercialization of plasmid-based drugs and vaccines will be accelerated by the opening of a new cGMP facility in Carlsbad, California. The facility will also be able to generate large amounts of plasmid DNA, which is a crucial component of drugs used in DNA treatments. This growth builds on the business's ongoing commitment to providing cell and gene therapy services.
• In May 2020, Takara Bio announced a collaboration with AGC Biologics. The businesses will collaborate on a prophylactic DNA vaccine against COVID-19, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine.

Gene synthesis and cloning represent fundamental techniques underpinning a broad range of scientific and biotechnological applications. DNA amplification methods such as subcloning and polymerase chain reaction (PCR) are widely employed as essential components of genetic cloning workflows. Recombinant DNA technology, also known as DNA cloning, involves the combination of genetic material from two different sources into a single DNA construct, which is then introduced into a host organism to generate genetically modified cells or organisms.

This technology is extensively utilized in applications including protein expression, functional gene analysis, and the development of gene-based therapeutic approaches. The standard process typically begins with the isolation of DNA from a source organism, followed by identification and amplification of the target gene using molecular cloning techniques. Key steps include plasmid DNA extraction, enzymatic digestion with restriction enzymes, and insertion of the recombinant DNA into a suitable host cell to enable replication. PCR plays a central role in amplifying specific DNA sequences throughout this workflow. Within the field of genetic engineering, gene cloning refers to the production of synthetic copies of genes for use in research, diagnostic applications, and therapeutic development.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Gene cloning can be accomplished through two primary approaches: in vivo and in vitro methods. A wide range of human genes has been successfully introduced into microbial hosts such as Escherichia coli and yeast, enabling efficient large-scale in vitro production of human proteins. At present, over one hundred therapeutic products are manufactured using genetically engineered cells-including E. coli, yeast, and mammalian systems-into which human gene sequences have been incorporated. Gene cloning has become a pivotal technology in biotechnology, driving significant advancements in healthcare by supporting the development of more effective treatments for chronic diseases and contributing to increased life expectancy. In agriculture, gene cloning is widely applied to improve crop quality, yield, and nutritional value.

The global market for DNA and gene cloning services is anticipated to experience steady growth in the coming years. This expansion is largely driven by the increasing adoption of gene therapy and continuous advancements in DNA cloning technologies. Growing investments in research and development, coupled with rising demand for personalized medicine, are further supporting market growth. The sector also benefits from strong funding inflows, ongoing technological progress, and the entry of new market participants.

Despite these positive trends, the gene synthesis and cloning market faces certain challenges, including a limited availability of skilled professionals and lengthy regulatory approval processes. However, ongoing technological innovation, along with strategic partnerships, mergers, and acquisitions within the biomedical and healthcare sectors, is expected to generate significant growth opportunities. Supported by strong capital investment and the expanding integration of gene cloning technologies into life sciences research-particularly in regions such as North America-the market is well positioned for sustained long-term growth.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1357

Market Segmentation:
Global DNA and Gene Cloning Services Market, by Type of Service Offered, 2023-2031 (Value US$ Mn)
• Custom Cloning
• Gene Synthesis
• Sub-cloning
• Others
Global DNA and Gene Cloning Services Market, by Type of Gene, 2023-2031 (Value US$ Mn)
• Complex Gene
• Standard Gene
• Others
Global DNA and Gene Cloning Services Market, by End-User Industry, 2023-2031 (Value US$ Mn)
• Academic and R&D
• Pharmaceutical and Biotechnology Companies
• Others
Global DNA and Gene Cloning Services Market, by Region, 2023-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• U.S.
• Canada
Europe DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa DNA and Gene Cloning Services Market, by Country, 2023-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-dna-and-gene-cloning-services-market-/1357

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.